High Expression of AHSP, EPB42, GYPC and HEMGN Predicts Favorable Prognosis in FLT3-ITD-Negative Acute Myeloid Leukemia
High Expression of AHSP, EPB42, GYPC and HEMGN Predicts Favorable Prognosis in FLT3-ITD-Negative Acute Myeloid Leukemia
复制标题
AHSP、EPB42、GYPC 和 HEMGN 的高表达预示着 FLT3-ITD 阴性急性髓系白血病的良好预后
DOI：
10.1159/000479837
复制
发表时间：
2017-08
影响因子：
--
通讯作者：
Chen Xiao Ping
中科院分区：
文献类型：
--
作者：
Zhu Gang Zhi;Yang Yong Long;Zhang Yan Jiao;Liu Wei;Li Mu Peng;Zeng Wen Jing;Zhao Xie Lan;Chen Xiao Ping
背景/目标：急性髓性白血病（AML）是一种异质性克隆性疾病，携带FMS样酪氨酸激酶3（FLT 3）突变的AML患者给临床医生带来了几个难题。本研究的目的是确定新的目标来解释的困境。方法：我们分析了四个微阵列基因表达谱，以研究与FLT 3-ITD突变相关的全基因组表达变化。结果：我们鉴定出22个差异表达基因，这些基因在所有四种基因型中普遍表达。Kaplan-Meier法分析GSE 12417数据集显示，AHSP、EPB 42、GYPC和HEGN的低表达预示预后不良（在GSE 12417测试队列中，AHSP：P= 0.0317，HR= 1.894; EPB 42：P=0.0382，HR=1.859; GYPC：P=0.0015，HR=2.051; HEMGN：P=0.0418，HR=1.838; AHSP：P=0.0279，HR=1.548; EPB 42：P=0.0398，HR=1.505; GYPC：P=0.0408，HR=1.501; HEMGN：P=0.0143，HR=1.630（GSE 12417验证队列）。当FLT 3-ITD阳性时，FLT 3的表达显著增加（4个谱均P<0.05），相关分析显示4个候选基因的表达与FLT 3的表达呈负相关。结论：我们的研究结果表明，α-血红蛋白稳定蛋白，EPB 42，GYPC和HEMGN可能是合适的生物标志物的FLT 3-ITD阳性AML患者的诊断或治疗策略。
Background/Aims: Acute myeloid leukemia (AML) is a heterogeneous clonal disease and patients with AML who harbor an FMS-like tyrosine kinase 3 (FLT3) mutation present several dilemmas for the clinician. This study aims to identify novel targets for explaining the dilemmas. Methods: We analyzed four microarray gene expression profiles to investigate changes in whole genome expression associated with FLT3-ITD mutation. Results: We identified 22 differentially expressed genes which are commonly expressed among all four profiles. Kaplan-Meier analysis of the dataset GSE12417 revealed that low expression of AHSP, EPB42, GYPC and HEMGN predicted poor prognosis (AHSP: P=0.0317, HR=1.894; EPB42: P=0.0382, HR=1.859; GYPC: P=0.0015, HR=2.051; HEMGN: P=0.0418, HR=1.838 in GSE12417 test cohort; AHSP: P=0.0279, HR=1.548; EPB42: P=0.0398, HR=1.505; GYPC: P=0.0408, HR=1.501; HEMGN: P=0.0143, HR=1.630 in GSE12417 validation cohort). When patients were FLT3-ITD positive, the expression of FLT3 was significantly increased (all P<0.05 in four profiles), and correleation analysis of four profiles revealed that the expression of the four candidate genes negatively correlated with FLT3 expression. Conclusions: Our findings suggest that AHSP, EPB42, GYPC and HEMGN may be suitable biomarkers for diagnostic or therapeutic strategies for FLT3-ITD-positive AML patients.
登录
查看更多内容
影响因子：
3
作者：
Favero ME;Costa FF
通讯作者：
Costa FF
影响因子：
--
作者：
Rong Zhang;Wei Yang;Ying Li;G. Zhang;Kun Yao;R. Hu;Bin Wu
通讯作者：
Rong Zhang;Wei Yang;Ying Li;G. Zhang;Kun Yao;R. Hu;Bin Wu
DOI：
10.1007/978-3-030-73227-1_13
发表时间：
2021
期刊：
Practical Oncologic Molecular Pathology
影响因子：
--
作者：
Guang Yang;Linsheng Zhang
通讯作者：
Guang Yang;Linsheng Zhang
DOI：
10.1016/b978-0-12-814482-4.00006-1
发表时间：
2020
期刊：
Computational Learning Approaches to Data Analytics in Biomedical Applications
影响因子：
--
作者：
Khalid Al-Jabery;Tayo Obafemi-Ajayi;G. Olbricht;D. Wunsch
通讯作者：
Khalid Al-Jabery;Tayo Obafemi-Ajayi;G. Olbricht;D. Wunsch
影响因子：
5.3
作者：
A. M. Pilon;Douglas G. Nilson;Dewang Zhou;J. Sangerman;T. Townes;D. Bodine;P. Gallagher
通讯作者：
A. M. Pilon;Douglas G. Nilson;Dewang Zhou;J. Sangerman;T. Townes;D. Bodine;P. Gallagher